Consistently greater improvements in most end points ( including worsening of asthma as predefined by specific lung function parameters or clinical symptoms ) were observed moving from formoterol to budesonide to budesonide/formoterol in both FAO + and FAO - patients , with generally greater than additive effects on lung function with budesonide/formoterol in FAO + patients .